Regeneron Says Drug Approval Irrelevant In Antitrust Case
By Matthew Perlman · July 27, 2026, 4:17 PM EDT
Regeneron told a Delaware federal court the recent regulatory approval of a new cholesterol drug is irrelevant to its case accusing Amgen of bundling Repatha with other medications, as the court...
To view the full article, register now.